Melatonin blocks a specific iron-driven cell death process surgeons have never been able to stop.
For as long as surgeons have reconstructed damaged flesh, the edges of transplanted tissue have remained vulnerable — too far from the blood supply, too exposed to the slow violence of ischemia. Researchers in China have now traced a key mechanism of that vulnerability to ferroptosis, a form of cell death driven by iron accumulation and lipid breakdown, and found that melatonin — a hormone most know only as a sleep aid — can interrupt it. Across human cells, mice, and macaques, the hormone preserved tissue, restored blood flow, and caused no harm, suggesting that one of medicine's most familiar supplements may have a quiet role to play in the operating room.
- Skin flap surgery saves lives after burns and trauma, but its outer edges routinely die — a failure that has resisted decades of surgical and pharmaceutical effort.
- A research team at Wenzhou Medical University identified ferroptosis, a cascade of iron-driven cellular self-destruction, as a central culprit in flap tissue loss.
- Melatonin blocked that cascade at multiple points — reducing iron buildup, halting lipid peroxidation, shielding mitochondria, and activating the cell's own antioxidant defenses through Nrf2/HO-1 signaling.
- Evidence held across three biological systems — lab-grown human cells, mice, and macaques — with improved tissue survival and new blood vessel formation at every level.
- Because melatonin already carries a strong human safety record and is widely available, the path from laboratory finding to clinical trial is shorter than it would be for an unknown compound.
Surgeons repairing burns, trauma, and tumor removal have long depended on random-pattern skin flaps — grafts that survive without relying on a single blood vessel. But that flexibility carries a persistent cost: the outer edges of these flaps, furthest from any blood supply, often die regardless. Ischemia and tissue necrosis remain unsolved problems, and researchers at Wenzhou Medical University decided to look more closely at why.
Their investigation led them to ferroptosis — a form of programmed cell death triggered by iron accumulation and the breakdown of lipids inside cells. More surprisingly, it led them to melatonin. In a study published in Burns & Trauma in early 2026, the team showed that the familiar sleep hormone could block ferroptosis and dramatically improve flap survival across three biological systems: human endothelial cells, laboratory mice, and macaques.
In mice, flaps treated with melatonin for seven days after surgery showed visibly larger areas of living tissue, stronger blood flow on imaging, better-preserved structure, and fewer dying cells. The treated animals also showed higher expression of markers tied to new blood vessel growth. In human cells under oxidative stress, melatonin restored the ability to survive, divide, migrate, and form vessel-like structures — the essential work of vascular repair.
The mechanism sharpened when researchers used erastin, a chemical that deliberately triggers ferroptosis. Melatonin interrupted the cascade at multiple points: it reduced reactive oxygen species, prevented iron from accumulating, protected mitochondria, and elevated two key antioxidant proteins, SLC7A11 and GPX4. This was not a general antioxidant effect — it was targeted interference with a specific injury pathway. Oral melatonin given to macaques produced the same results, with no adverse findings on blood or biochemical tests.
What gives this discovery practical weight is melatonin's existing profile. It is already used in cancer care, cardiac protection, and neurological conditions, with a long record of human safety. For burn specialists and reconstructive surgeons, a widely available supplement that limits ferroptosis and preserves blood flow could reduce repeat surgeries and improve healing. Dosing, timing, and delivery still need to be worked out, but the preclinical case has been made — and the clinic is the logical next step.
Surgeons have long relied on random-pattern skin flaps to repair damage from burns, trauma, and tumor removal. These flaps offer flexibility because they don't depend on a single blood vessel to survive. But that same flexibility comes with a cost: the outer edges of the flap, furthest from the blood supply, often die anyway. Ischemia, inflammation, and tissue death remain stubborn problems even with current surgical and pharmaceutical approaches. Researchers at Wenzhou Medical University and partner institutions set out to understand why, and what might stop it.
Their answer came from an unexpected direction: melatonin, the hormone already familiar to millions as a sleep aid. In a study published in Burns & Trauma in February 2026, the team showed that melatonin could dramatically improve flap survival by blocking a specific form of cell death called ferroptosis—a process driven by iron accumulation and lipid breakdown inside cells. The finding emerged from careful work across three biological systems: human cells in a dish, mice in the lab, and macaques as a closer model to human physiology.
The researchers began with mice. They created random skin flaps surgically, then treated one group with melatonin for seven days after the operation while controls received saline. The difference was visible and measurable. Melatonin-treated flaps showed larger areas of viable tissue, stronger blood flow signals on laser Doppler imaging, better-preserved tissue structure, and fewer dying cells. The treated flaps also expressed higher levels of markers associated with new blood vessel formation—CD31, E-cadherin, and MMP9. In parallel, the team worked with human endothelial cells, the cells that line blood vessels. When they exposed these cells to oxidative stress, melatonin restored their ability to survive, multiply, migrate, and form new tube-like structures—the basic work of vascular repair.
The critical insight came when researchers deliberately induced ferroptosis in cells using erastin, a chemical ferroptosis trigger. Melatonin blocked the cascade. It reduced reactive oxygen species and lipid peroxidation. It stopped iron from accumulating inside cells. It protected mitochondria from damage. And it boosted the cell's own antioxidant defenses, particularly by increasing expression of two protective genes, SLC7A11 and GPX4, along with their corresponding proteins. The mechanism became clear: melatonin wasn't just generally mopping up oxidative stress. It was interrupting a specific injury pathway in which iron and lipid breakdown push ischemic tissue toward ferroptosis.
To test whether this mechanism held in a larger animal, the researchers gave oral melatonin to macaques. Again, flap survival improved. Necrotic changes decreased. New blood vessels formed. Routine blood work and biochemical tests showed no adverse effects. The cross-species evidence—cells, mice, primates—strengthened the biological link between ferroptosis control and flap survival.
What makes this finding potentially significant for clinical practice is not just the mechanism but the messenger. Melatonin is already widely available as a dietary supplement. It has a long safety record in humans, including use in cancer treatment, heart protection, and neurodegenerative disease. It is not an exotic experimental compound requiring years of toxicology work. For reconstructive surgeons, burn specialists, and trauma teams, a treatment that preserves blood flow while limiting ferroptosis could reduce the need for repeat surgeries and improve healing outcomes. The researchers acknowledge that work remains: optimal dosing, timing, delivery method, and long-term patient outcomes all need definition. But they have provided the preclinical foundation. The next step is the clinic.
Citas Notables
Melatonin does more than generally reduce oxidative stress. It appears to interrupt a specific injury process in which iron accumulation and lipid peroxidation push ischemic flap tissue toward ferroptosis.— Study authors
Melatonin is already widely utilized as a dietary supplement for sleep regulation and has demonstrated a favorable safety profile across various clinical applications.— Study authors
La Conversación del Hearth Otra perspectiva de la historia
Why does the outer edge of a skin flap die so reliably? It seems like a problem surgeons would have solved by now.
The outer edge is the farthest from the blood supply. When you cut and move tissue, you interrupt its normal blood flow. The edge gets starved of oxygen, then when blood flow returns, it causes damage. Current approaches address inflammation and general oxidative stress, but they don't stop this specific iron-driven cell death process—ferroptosis.
So melatonin is doing something different than just being an antioxidant?
Exactly. It's not just mopping up free radicals. It's blocking iron accumulation and lipid breakdown inside cells, and it's activating specific protective genes. It's targeting the mechanism, not the symptom.
The study tested this in mice and macaques. Why not jump straight to human trials?
Preclinical work has to establish safety and mechanism first. You need to know it works across different biological systems before you give it to patients. The macaque data is important because primates are closer to humans physiologically than mice are.
What's the practical advantage of using melatonin over a new drug?
It's already on the market. Millions of people take it safely for sleep. That means the regulatory pathway is shorter, the safety profile is known, and hospitals could potentially use it tomorrow if clinical trials confirm it works in humans.
What would a surgeon actually do differently?
After flap surgery, instead of just managing pain and infection, they'd give melatonin—probably orally—for a week or more. If it works in humans the way it did in animals, more of the flap survives, fewer patients need revision surgery, and healing is faster.
What's the biggest remaining question?
Dosing and timing in actual patients. The animal studies used specific doses over specific periods. Human bodies are more variable. You need to know the right amount, when to start, how long to continue, and whether it works equally well in different types of flaps and different patient populations.